Examination of the neural pathways upstream of vascular activity in migraine has given rise to therapies that target the actions of CGRP.[Karsan & Goadsby, 2015] As outlined on the slide, CGRP is a small peptide that is thought to be crucial in migraine pathology.[Karsan & Goadsby, 2015] Approaches to targeting CGRP include small molecule antagonists, and antibodies directed at the protein or at its receptor.[Karsan & Goadsby, 2015]
Reference:
Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015; 15 (5): 25.
Other references used on slide:
CGRP Forum. A background to CGRP and its receptor.
Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain 2017; 18 (1): 96.
Dos Santos JBR, da Silva MRR. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Eur J Pharmacol. 2022 May 5;922:174902. doi: 10.1016/j.ejphar.2022.174902. Epub 2022 Mar 28. PMID: 35358493.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28 (2): 183–187.
Guo S, Christensen AF, Liu ML, et al. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia 2017; 37 (2): 114–124.
Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics 2018; 15 (2): 304–312.
Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014; 94 (4): 1099–1142.
